Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

doi:10.1038/s41591-019-0654-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

Nature medicine - 1 Dec 2019

Liu David, Schilling Bastian, Liu Derek, Sucker Antje, Livingstone Elisabeth, Jerby-Arnon Livnat, Zimmer Lisa, Gutzmer Ralf, Satzger Imke, Loquai Carmen, Grabbe Stephan, Vokes Natalie, Margolis Claire A, Conway Jake, He Meng Xiao, Elmarakeby Haitham, Dietlein Felix, Miao Diana, Tracy Adam, Gogas Helen, Goldinger Simone M, Utikal Jochen, Blank Christian U, Rauschenberg Ricarda, von Bubnoff Dagmar, Krackhardt Angela, Weide Benjamin, Haferkamp Sebastian, Kiecker Felix, Izar Ben, Garraway Levi, Regev Aviv, Flaherty Keith, Paschen Annette, Van Allen Eliezer M, Schadendorf Dirk

Abstract excerpt

Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study, we analyzed a clinically annotated cohort of patients with melanoma (n = 144) treated with anti-PD1 ICB, with whole-exome and whole-transcriptome sequencing of pre-treatment tumors. We found that tumor mutational burden as a predictor of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigen Presentation

Share to CTLA-4 Antigen

Share to Exome Sequencing

Share to Melanoma

Share to Neoplasm Metastasis

Share to Nivolumab

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 31792460
DOI: 10.1038/s41591-019-0654-5
PMCID: PMC6898788

Genes

CTLA4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.PMID 31792460Read ↗

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.Semantic proximity Read ↗

Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanomaSemantic proximity Read ↗

Transcriptional analysis of immune modulatory genes in melanoma treated with PD-1 blockadeSemantic proximity Read ↗

Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironmentSemantic proximity Read ↗

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity Read ↗

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma.Semantic proximity Read ↗

Integrative Multi-Omics Analysis of Melanoma: Uncovering Pathways Associated with Immunotherapy OutcomesSemantic proximity Read ↗

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSemantic proximity Read ↗

Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic cutaneous melanomaSemantic proximity Read ↗

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanomaSemantic proximity Read ↗

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSemantic proximity Read ↗

AI Model for Predicting Anti-PD1 Response in Melanoma Using Multi-Omics BiomarkersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.